Module 1: Overview of Intrathecal Therapy For Chronic Pain

This CME/CE-accredited CMESnapshot™ four-part series is intended for pain specialists, pain management nurses, and other clinicians who manage patients treated with intrathecally delivered analgesics for chronic pain. The faculty will also review freely available patient- and caregiver-directed educational resources that seek to improve shared decision-making.

Target Audience

These activities have been designed to meet the educational needs of pain specialists, pain management nurses, and other clinicians who manage patients treated with intrathecally delivered analgesics for chronic pain.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. Describe the rationale and appropriate roles of intrathecal drug delivery as a treatment option for severe chronic pain

Faculty

 

Charles E. Argoff, MD
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, New York

Timothy R. Deer, MD, DABPM
President and Chief Executive Officer
The Center for Pain Relief, Inc.
Spine and Nerve Centers of the Virginias
Charleston, West Virginia

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:

Name of Faculty or Presenter

Relationship Identified With:

Charles E. Argoff, MD

Consultant/Advisor: Depomed, Inc., Grünenthal GmbH, Nevro Corp., Pfizer Inc., Purdue Pharma L.P., Theranica Ltd.

Speakers’ Bureau: Allergan USA, Inc., BioDelivery Sciences International, Inc., Collegium Pharmaceutical, Inc., Depomed, Inc., Jazz Pharmaceuticals, Inc.

Stock Ownership: Depomed, Inc., Pfizer Inc.

Grant/Research Support: Grünenthal GmbH, Theranica Ltd.

Royalties, Patents: Elsevier

Timothy R. Deer, MD, DABPM

Consultant/Advisor: Flowonix Medical Inc., SPG Therapeutics Inc., SpineThera, Inc.

Speakers’ Bureau: Jazz Pharmaceuticals, Inc.

Non-faculty: Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.

Financial Support

These activities have been supported by an independent educational grant from Jazz Pharmaceuticals, Inc.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education, Dannemiller, and Integritas Communications. 

CME Credit (Physicians)

These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates each enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.

AANP CREDIT (NURSE PRACTITIONERS)

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Dannemiller the Elsevier Office of Continuing Medical Education. Dannemiller is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 090419. This program is accredited for 0.25 contact hour(s) which includes 0.0 hours of pharmacology.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Elsevier Office of Continuing Medical Education, Dannemiller, Integritas Communications, and Jazz Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.25 AANP
  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician
Course opens: 
08/15/2018
Course expires: 
08/14/2019
Rating: 
0

Available Credit

  • 0.25 AANP
  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician

Accreditation Period

Course opens: 
08/15/2018
Course expires: 
08/14/2019
Please login or register to take this course.